129 related articles for article (PubMed ID: 37310065)
21. Knockdown of tripartite motif 59 (TRIM59) inhibits proliferation in cholangiocarcinoma via the PI3K/AKT/mTOR signalling pathway.
Shen H; Zhang J; Zhang Y; Feng Q; Wang H; Li G; Jiang W; Li X
Gene; 2019 May; 698():50-60. PubMed ID: 30822475
[TBL] [Abstract][Full Text] [Related]
22. Notch and mTOR Signaling Pathways Promote Human Gastric Cancer Cell Proliferation.
Hibdon ES; Razumilava N; Keeley TM; Wong G; Solanki S; Shah YM; Samuelson LC
Neoplasia; 2019 Jul; 21(7):702-712. PubMed ID: 31129492
[TBL] [Abstract][Full Text] [Related]
23. Pathological diagnosis of flat epithelial lesions of the biliary tract with emphasis on biliary intraepithelial neoplasia.
Sato Y; Sasaki M; Harada K; Aishima S; Fukusato T; Ojima H; Kanai Y; Kage M; Nakanuma Y; Tsubouchi H;
J Gastroenterol; 2014 Jan; 49(1):64-72. PubMed ID: 23616173
[TBL] [Abstract][Full Text] [Related]
24. Notch2 controls hepatocyte-derived cholangiocarcinoma formation in mice.
Wang J; Dong M; Xu Z; Song X; Zhang S; Qiao Y; Che L; Gordan J; Hu K; Liu Y; Calvisi DF; Chen X
Oncogene; 2018 Jun; 37(24):3229-3242. PubMed ID: 29545603
[TBL] [Abstract][Full Text] [Related]
25. Intraductal papillary neoplasms of the bile duct: stepwise progression to carcinoma involves common molecular pathways.
Schlitter AM; Born D; Bettstetter M; Specht K; Kim-Fuchs C; Riener MO; Jeliazkova P; Sipos B; Siveke JT; Terris B; Zen Y; Schuster T; Höfler H; Perren A; Klöppel G; Esposito I
Mod Pathol; 2014 Jan; 27(1):73-86. PubMed ID: 23828315
[TBL] [Abstract][Full Text] [Related]
26. New molecular mechanisms in cholangiocarcinoma: signals triggering interleukin-6 production in tumor cells and KRAS co-opted epigenetic mediators driving metabolic reprogramming.
Colyn L; Alvarez-Sola G; Latasa MU; Uriarte I; Herranz JM; Arechederra M; Vlachogiannis G; Rae C; Pineda-Lucena A; Casadei-Gardini A; Pedica F; Aldrighetti L; López-López A; López-Gonzálvez A; Barbas C; Ciordia S; Van Liempd SM; Falcón-Pérez JM; Urman J; Sangro B; Vicent S; Iraburu MJ; Prosper F; Nelson LJ; Banales JM; Martinez-Chantar ML; Marin JJG; Braconi C; Trautwein C; Corrales FJ; Cubero FJ; Berasain C; Fernandez-Barrena MG; Avila MA
J Exp Clin Cancer Res; 2022 May; 41(1):183. PubMed ID: 35619118
[TBL] [Abstract][Full Text] [Related]
27. Genetic Screens Identify a Context-Specific PI3K/p27Kip1 Node Driving Extrahepatic Biliary Cancer.
Falcomatà C; Bärthel S; Ulrich A; Diersch S; Veltkamp C; Rad L; Boniolo F; Solar M; Steiger K; Seidler B; Zukowska M; Madej J; Wang M; Öllinger R; Maresch R; Barenboim M; Eser S; Tschurtschenthaler M; Mehrabi A; Roessler S; Goeppert B; Kind A; Schnieke A; Robles MS; Bradley A; Schmid RM; Schmidt-Supprian M; Reichert M; Weichert W; Sansom OJ; Morton JP; Rad R; Schneider G; Saur D
Cancer Discov; 2021 Dec; 11(12):3158-3177. PubMed ID: 34282029
[TBL] [Abstract][Full Text] [Related]
28. The Hippo pathway effector TAZ induces intrahepatic cholangiocarcinoma in mice and is ubiquitously activated in the human disease.
Cigliano A; Zhang S; Ribback S; Steinmann S; Sini M; Ament CE; Utpatel K; Song X; Wang J; Pilo MG; Berger F; Wang H; Tao J; Li X; Pes GM; Mancarella S; Giannelli G; Dombrowski F; Evert M; Calvisi DF; Chen X; Evert K
J Exp Clin Cancer Res; 2022 Jun; 41(1):192. PubMed ID: 35655220
[TBL] [Abstract][Full Text] [Related]
29. DMBT1 expression in biliary carcinogenesis with correlation of clinicopathological data.
Goeppert B; Roessler S; Becker N; Zucknick M; Vogel MN; Warth A; Pathil-Warth A; Mehrabi A; Schirmacher P; Mollenhauer J; Renner M
Histopathology; 2017 Jun; 70(7):1064-1071. PubMed ID: 28130841
[TBL] [Abstract][Full Text] [Related]
30. Different carcinogenic process in cholangiocarcinoma cases epidemically developing among workers of a printing company in Japan.
Sato Y; Kubo S; Takemura S; Sugawara Y; Tanaka S; Fujikawa M; Arimoto A; Harada K; Sasaki M; Nakanuma Y
Int J Clin Exp Pathol; 2014; 7(8):4745-54. PubMed ID: 25197345
[TBL] [Abstract][Full Text] [Related]
31. Kras
Chung WC; Wang J; Zhou Y; Xu K
Oncoscience; 2017 Sep; 4(9-10):131-138. PubMed ID: 29142904
[TBL] [Abstract][Full Text] [Related]
32. Comparison of CT findings of biliary tract changes with autoimmune pancreatitis and extrahepatic bile duct cholangiocarcinoma.
Maeda E; Akahane M; Yoshioka N; Takao H; Matsuda I; Kamiya K; Hirano K; Tada M; Ohtsu H; Fukushima N; Ohtomo K
Jpn J Radiol; 2012 Apr; 30(3):227-34. PubMed ID: 22200917
[TBL] [Abstract][Full Text] [Related]
33. Sox9 expression in carcinogenesis and its clinical significance in intrahepatic cholangiocarcinoma.
Matsushima H; Kuroki T; Kitasato A; Adachi T; Tanaka T; Hirabaru M; Hirayama T; Kuroshima N; Hidaka M; Soyama A; Takatsuki M; Kinoshita N; Sano K; Nishida N; Eguchi S
Dig Liver Dis; 2015 Dec; 47(12):1067-75. PubMed ID: 26341967
[TBL] [Abstract][Full Text] [Related]
34. Imaging Features of Premalignant Biliary Lesions and Predisposing Conditions with Pathologic Correlation.
Zulfiqar M; Chatterjee D; Yoneda N; Hoegger MJ; Ronot M; Hecht EM; Bastati N; Ba-Ssalamah A; Bashir MR; Fowler K
Radiographics; 2022; 42(5):1320-1337. PubMed ID: 35930475
[TBL] [Abstract][Full Text] [Related]
35. MYC-binding lncRNA EPIC1 promotes AKT-mTORC1 signaling and rapamycin resistance in breast and ovarian cancer.
Wang Y; Zhang M; Wang Z; Guo W; Yang D
Mol Carcinog; 2020 Oct; 59(10):1188-1198. PubMed ID: 32810332
[TBL] [Abstract][Full Text] [Related]
36. Oncogenic potential of IDH1R132C mutant in cholangiocarcinoma development in mice.
Ding N; Che L; Li XL; Liu Y; Jiang LJ; Fan B; Tao JY; Chen X; Ji JF
World J Gastroenterol; 2016 Feb; 22(6):2071-80. PubMed ID: 26877611
[TBL] [Abstract][Full Text] [Related]
37. Hepatoid carcinoma and related entities of the extrahepatic bile duct: A clinicopathological study of four cases.
Okura K; Esaki M; Nara S; Ban D; Takamoto T; Shimada K; Hiraoka N
Pathol Int; 2022 Jun; 72(6):332-342. PubMed ID: 35472251
[TBL] [Abstract][Full Text] [Related]
38. 4EBP1/eIF4E and p70S6K/RPS6 axes play critical and distinct roles in hepatocarcinogenesis driven by AKT and N-Ras proto-oncogenes in mice.
Wang C; Cigliano A; Jiang L; Li X; Fan B; Pilo MG; Liu Y; Gui B; Sini M; Smith JW; Dombrowski F; Calvisi DF; Evert M; Chen X
Hepatology; 2015 Jan; 61(1):200-13. PubMed ID: 25145583
[TBL] [Abstract][Full Text] [Related]
39. Pan-mTOR inhibitor MLN0128 is effective against intrahepatic cholangiocarcinoma in mice.
Zhang S; Song X; Cao D; Xu Z; Fan B; Che L; Hu J; Chen B; Dong M; Pilo MG; Cigliano A; Evert K; Ribback S; Dombrowski F; Pascale RM; Cossu A; Vidili G; Porcu A; Simile MM; Pes GM; Giannelli G; Gordan J; Wei L; Evert M; Cong W; Calvisi DF; Chen X
J Hepatol; 2017 Dec; 67(6):1194-1203. PubMed ID: 28733220
[TBL] [Abstract][Full Text] [Related]
40. Early activation of mTORC1 signalling in response to mechanical overload is independent of phosphoinositide 3-kinase/Akt signalling.
Miyazaki M; McCarthy JJ; Fedele MJ; Esser KA
J Physiol; 2011 Apr; 589(Pt 7):1831-46. PubMed ID: 21300751
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
